Viracta Therapeutics, Inc. (VIRX) Financial Statements (2026 and earlier)

Company Profile

Business Address 2533 S COAST HWY 101
CARDIFF, CA 92007
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:53,700,00091,000,000103,554,00020,410,00029,125,00013,696,000
Cash and cash equivalent12,317,00036,773,000103,554,00020,410,00012,761,00013,696,000
Short-term investments41,374,00054,270,000  16,364,000 
Other undisclosed cash, cash equivalents, and short-term investments9,000(43,000)    
Restricted cash and investments     5,500,000 
Prepaid expense 1,273,000     
Deposits current assets 135,000     
Other undisclosed current assets(144,000)2,747,0001,719,0001,734,0001,697,0001,504,000
Total current assets:54,964,00093,747,000105,273,00022,144,00036,322,00015,200,000
Noncurrent Assets
Operating lease, right-of-use asset 274,000266,000640,000273,000817,000
Property, plant and equipment190,000148,000242,000 3,00011,000
Other noncurrent assets1,264,0001,830,0002,397,000830,00098,000113,000
Total noncurrent assets:1,728,0002,244,0003,279,0001,103,000918,000124,000
TOTAL ASSETS:56,692,00095,991,000108,552,00023,247,00037,240,00015,324,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,817,0009,733,0008,703,0002,950,0002,885,0003,427,000
Employee-related liabilities 1,384,000985,000943,000
Accounts payable2,441,0002,540,0002,901,000479,000791,0001,393,000
Accrued liabilities10,376,0007,193,0005,802,0001,087,0001,109,0001,091,000
Debt25,274,000   6,010,0007,396,000
Other undisclosed current liabilities 282,000278,000381,000360,000521,000500,000
Total current liabilities:38,373,00010,011,0009,084,0003,310,0009,416,00011,323,000
Noncurrent Liabilities
Long-term debt and lease obligation  24,877,0005,097,000 272,000 
Long-term debt, excluding current maturities  24,877,0004,819,000   
Liabilities, other than long-term debt     9,0008,000
Other liabilities     9,0008,000
Operating lease, liability   278,000 272,000
Total noncurrent liabilities:  24,877,0005,375,000 281,0008,000
Total liabilities:38,373,00034,888,00014,459,0003,310,0009,697,00011,331,000
Equity
Equity, attributable to parent18,319,00061,103,00094,371,00019,937,00027,543,0003,993,000
Preferred stock 5,452,0005,452,0005,452,0005,545,00011,769,00020,998,000
Common stock4,0004,0004,0002,00011,0004,000
Additional paid in capital278,786,000270,699,000254,592,000718,800,000698,562,000642,460,000
Accumulated other comprehensive income (loss)9,000(178,000)  1,000 
Accumulated deficit(265,932,000)(214,874,000)(165,677,000)(704,410,000)(682,800,000)(659,469,000)
Total equity:18,319,00061,103,00094,371,00019,937,00027,543,0003,993,000
Other undisclosed liabilities and equity   (278,000)   
TOTAL LIABILITIES AND EQUITY:56,692,00095,991,000108,552,00023,247,00037,240,00015,324,000

Income Statement (P&L) (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues   120,0002,073,000237,000
Realized investment gains      
Gross profit:   120,0002,073,000237,000
Operating expenses(50,693,000)(50,589,000)(127,776,000)(22,423,000)(25,361,000)(25,947,000)
Other undisclosed operating income (loss)  13,500,000   
Operating loss:(50,693,000)(50,589,000)(114,276,000)(22,303,000)(23,288,000)(25,710,000)
Nonoperating income (expense)(365,000)1,392,000(486,000)995,000472,000249,000
Other nonoperating income (expense)(365,000)1,392,000(486,000)995,000472,000249,000
Interest and debt expense(3,704,000)(577,000)(491,000)(302,000)(514,000)(1,154,000)
Loss from continuing operations before equity method investments, income taxes:(54,762,000)(49,774,000)(115,253,000)(21,610,000)(23,330,000)(26,615,000)
Other undisclosed income from continuing operations before income taxes    1,000  
Loss from continuing operations:(54,762,000)(49,774,000)(115,253,000)(21,609,000)(23,330,000)(26,615,000)
Loss before gain (loss) on sale of properties:(115,253,000)(21,609,000)(23,330,000)(26,615,000)
Other undisclosed net loss    (1,000)  
Net loss:(54,762,000)(49,774,000)(115,253,000)(21,610,000)(23,330,000)(26,615,000)
Other undisclosed net income attributable to parent3,704,000577,000491,000   
Net loss available to common stockholders, diluted:(51,058,000)(49,197,000)(114,762,000)(21,610,000)(23,330,000)(26,615,000)

Comprehensive Income (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(54,762,000)(49,774,000)(115,253,000)(21,610,000)(23,330,000)(26,615,000)
Comprehensive loss:(54,762,000)(49,774,000)(115,253,000)(21,610,000)(23,330,000)(26,615,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3,891,000399,000 (1,000)1,0007,000
Comprehensive loss, net of tax, attributable to parent:(50,871,000)(49,375,000)(115,253,000)(21,611,000)(23,329,000)(26,608,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: